Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Impact of addition of BMS-275291 to paclitaxel/carboplatin examined in phase II/III trial in NSCLC

Oct. 26, 2001

Catalytic antioxidant AEOL-10150 protects hamsters against radiation-induced mucositis

Oct. 26, 2001

Combination of CCI-779 and 5-FU/LV associated with significant toxicity in phase I study

Oct. 26, 2001

Patent coverage obtained for new myt1 kinase inhibitors

Oct. 25, 2001

Geron grants Dendreon nonexclusive license for telomerase technology

Oct. 25, 2001

Combination therapy with PKC-412, 5-FU and leucovorin evaluated in phase I trial

Oct. 25, 2001

Cell Therapeutics and Chugai establish agreement to develop cancer product

Oct. 25, 2001

Minimal toxicity seen in phase I studies of new camptothecin conjugate

Oct. 25, 2001

U.S. clinical trials of new polyamine drug SL-11047 will now begin

Oct. 25, 2001

Clinical testing of NIK-333 commences

Oct. 25, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...